Format

Send to

Choose Destination
J Comp Eff Res. 2015 Aug;4(4):303-14. doi: 10.2217/cer.15.19.

Costs and mortality of recurrent versus de novo hormone receptor-positive/HER2(-) metastatic breast cancer.

Author information

1
Senior Researcher, Optum, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA.
2
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Abstract

AIM:

To examine cost and mortality differences in postmenopausal women with HR(+)/HER2(-) advanced breast cancer.

METHODS:

Using claims data (2007-2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified.

RESULTS:

Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents. Adjusted per patient per month costs for early-recurrent patients were US$13,404, versus US$9955 (de novo) and US$9721 (late-recurrent; p = 0.02). Early-recurrent patients' risk of death was twice that of de novo patients (p = 0.02).

CONCLUSION:

Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.

KEYWORDS:

HER2-; breast cancer; claims analysis; costs; estrogen receptor positive; hormone receptor positive; mortality; retrospective analysis

PMID:
26274792
DOI:
10.2217/cer.15.19
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center